They’re not just pills—they’re precision infusions designed to slow Alzheimer’s at its source. See UCLA’s cutting-edge Amyloid Immunotherapy Care Program, and what it feels like to begin treatment with Leqembi (lecanemab) and Kisunla (donanemab).
FDA approves a newly recommended dosing schedule for Kisunla (Donanemab). It’s significantly safer due to lowered ARIA-E rates, which has been the main problem with these drugs.
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
The 2 newest Alzheimer’s drugs, Leqembi (lecanemab) and Kisunla (donanemab) show promise, but many questions remain. Here are the three next ones.
Right now, there are two FDA approved drugs to treat Alzheimer’s itself. Find out why Remternetug may soon get approval as a third, even better treatment.
Kisunla, the newest Alzheimer’s drug, is rapidly gaining acceptance around the world. Learn what it does and how to get it.
Ely Lilly unveils new $1,000,000,000 facility for drugs including Kisunla for Alzheimer’s. New investment will enhance global medicine production, benefiting millions of patients worldwide
The newest Alzheimer’s drugs, Kisunla and Leqembi, are the first to actually slow down Alzheimer’s. How do they compare to each other?
VIDEO + ARTICLE: Kisunla (generic name: Donanemab) slowed cognitive and functional decline 35%. Once-monthly infusions reduced Alzheimer’s plaque 84%.
Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?